A Pilot Study of Exercise in Patients With Docetaxel-Based Chemotherapy for Hormone Refractory Prostate Cancer
NCT ID: NCT00271687
Last Updated: 2016-02-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
30 participants
INTERVENTIONAL
2006-02-28
2007-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Adjuvant High-intensity Interval Training During Chemotherapy in Metastatic Prostate Cancer Patients
NCT05156372
Exercise Intervention Among Men With Prostate Cancer Initiating Androgen Deprivation Therapy
NCT03070145
Exercise for Advanced Prostate Cancer: a Multicomponent Feasibility Trial
NCT03658486
Exercise Prescription Dose for Castration Resistance Prostate Cancer Patients
NCT03526562
Feasibility of Measuring Exercise's Effects on Molecular Mechanisms of Disease Progression in Prostate Cancer
NCT02481648
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Exercise training
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* receiving docetaxel-based chemotherapy at the CCI
* age 18 years or over
* approval of oncologist
* informed written consent
Exclusion Criteria
* Karnofsky performance score less than 70
* contraindications for exercise (e.g. uncontrolled cardiac, respiratory, hypertensive or psychiatric disorder)
* unable to understand, read, write and speak English
* unable or unwilling to attend supervised exercise sessions 3 times weekly
* unable or unwilling to complete outcome assessments
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cross Cancer Institute
OTHER
AHS Cancer Control Alberta
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kerry Courneya, M.D.
Role: PRINCIPAL_INVESTIGATOR
Cross Cancer Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cross Cancer Institute
Edmonton, Alberta, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SP-14-0049 / 22262
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.